RT Journal
A1 Friedrich MJ
T1 HIv trial modification
JF JAMA
JO JAMA
YR 2012
FD January 18
VO 307
IS 3
SP 243
OP 243
DO 10.1001/jama.2011.1976
UL http://dx.doi.org/10.1001/jama.2011.1976
AB 
Based on the recommendations of the independent data and safety monitoring board (DSMB) of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, the investigators will discontinue the section of the trial that involved participants receiving the tenofovir or placebo gels but will continue with a group who is receiving a pill containing 2 drugs (tenofovir and another anti-HIV drug, emtricitabine) or placebo.